Story Stocks^®

Abbott Laboratories’ (ABT) 3Q25 results were generally in line with expectations, consistent with its pattern of steady performance. Revenue rose 6.9% yr/yr to $11.37 bln, or 7.5% excluding COVID-19 testing-related sales, while EPS landed near consensus estimates. FY25 EPS guidance was maintained at $5.12–$5.18, with organic sales growth reaffirmed at +7.5–8.0%. Results and guidance come across as somewhat underwhelming, reflected in today’s stock weakness.

• Medical Devices led growth, up 12.5% organically to $5.4 bln, driven by double-digit gains in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure, and Structural Heart. Continuous Glucose Monitor (CGM) sales reached $2.0 bln, up 20.5%, supported by FreeStyle Libre adoption and new product launches.
• Established Pharmaceuticals grew 7.1% organically, with emerging markets up 11.1%, led by Creon, Duphaston, and Brufen across Asia, Latin America, and the Middle East.
• Diagnostics declined 7.8% organically as COVID-19 testing dropped 74% to $69 mln. Excluding COVID products, revenue edged up 0.4%, weighed down by soft demand in China and volume-based procurement programs.

Briefing.com Analyst Insight:

ABT’s Q3 results reflect its typical steady execution but lacked significant upside. Medical Devices remains the primary growth engine, fueled by CGM and cardiac device adoption. Established Pharmaceuticals provides reliable contributions from emerging markets, while Diagnostics normalizes post-pandemic. The reaffirmed full-year outlook signals confidence but offers little new excitement. Investors may await stronger catalysts, such as faster Libre adoption or new device approvals, to drive stock momentum. Overall, while ABT remains a solid, predictable performer, near-term upside appears limited without incremental innovation or market expansion.